Capricor Therapeutics presented data from HOPE-3 Open Label Extension study at the 2026 World Muscle Society Congress indicating that deramiocel treatment is associated with a slower decline in upper limb […]
ELEVIDYS Data Read the press release and letter to the community:
Secretome Therapeutics has initiated an open label phase 2 study to evaluate the safety and potential skeletal muscle and cardiac effects of STM-01, an investigational cell therapy derived from cardiac progenitor cells. […]
As an early funder of Avidity Biosciences, we are pleased to share that Novartis has announced that the FDA has accepted the Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for Priority […]
Proposed text: CureDuchenne was an early funder of Sarepta Therapeutics, and we are pleased to share that the US FDA has accepted supplemental New Drug Applications (sNDAs) for AMONDYS 45 […]
As a founding partner and initial funder of the Collaborative Trajectory Analysis Project (cTAP), CureDuchenne is proud to support an important advancement for the Duchenne community: a novel prognostic score that helps […]
Emerging guidance offers cautious optimism—here’s what parents and caregivers should know For years, families affected by Duchenne muscular dystrophy have heard a consistent message: “be cautious with exercise, don’t overdo it.” That guidance came from a […]
What Sarepta Therapeutics’ sNDA submission means for Duchenne Sarepta Therapeutics is preparing to submit supplemental new drug applications (sNDAs) to the FDA for converting the accelerated approvals of AMONDYS 45 […]
ITF shared a community letter and presented new data, including long-term safety observations based on data from the company’s ongoing open-label extension study in patients with Duchenne muscular dystrophy treated with […]
